These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18245549)

  • 1. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma.
    Dummer R; Hauschild A; Becker JC; Grob JJ; Schadendorf D; Tebbs V; Skalsky J; Kaehler KC; Moosbauer S; Clark R; Meng TC; Urosevic M
    Clin Cancer Res; 2008 Feb; 14(3):856-64. PubMed ID: 18245549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.
    Dudek AZ; Yunis C; Harrison LI; Kumar S; Hawkinson R; Cooley S; Vasilakos JP; Gorski KS; Miller JS
    Clin Cancer Res; 2007 Dec; 13(23):7119-25. PubMed ID: 18056192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous pharmacodynamics of a toll-like receptor 7 agonist, 852A, in humans.
    Astry C; Birmachu W; Harrison LI; Meng TC
    J Clin Pharmacol; 2008 Jun; 48(6):755-62. PubMed ID: 18401016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
    Pashenkov M; Goëss G; Wagner C; Hörmann M; Jandl T; Moser A; Britten CM; Smolle J; Koller S; Mauch C; Tantcheva-Poor I; Grabbe S; Loquai C; Esser S; Franckson T; Schneeberger A; Haarmann C; Krieg AM; Stingl G; Wagner SN
    J Clin Oncol; 2006 Dec; 24(36):5716-24. PubMed ID: 17179105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans.
    Harrison LI; Astry C; Kumar S; Yunis C
    J Clin Pharmacol; 2007 Aug; 47(8):962-9. PubMed ID: 17660481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.
    Inglefield JR; Dumitru CD; Alkan SS; Gibson SJ; Lipson KE; Tomai MA; Larson CJ; Vasilakos JP
    J Interferon Cytokine Res; 2008 Apr; 28(4):253-63. PubMed ID: 18439103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies.
    Weigel BJ; Cooley S; DeFor T; Weisdorf DJ; Panoskaltsis-Mortari A; Chen W; Blazar BR; Miller JS
    Am J Hematol; 2012 Oct; 87(10):953-6. PubMed ID: 22718533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
    Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
    Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
    Hammerbeck DM; Burleson GR; Schuller CJ; Vasilakos JP; Tomai M; Egging E; Cochran FR; Woulfe S; Miller RL
    Antiviral Res; 2007 Jan; 73(1):1-11. PubMed ID: 16959331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
    Davis ID; Skrumsager BK; Cebon J; Nicholaou T; Barlow JW; Moller NP; Skak K; Lundsgaard D; Frederiksen KS; Thygesen P; McArthur GA
    Clin Cancer Res; 2007 Jun; 13(12):3630-6. PubMed ID: 17575227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
    Hauschild A; Trefzer U; Garbe C; Kaehler KC; Ugurel S; Kiecker F; Eigentler T; Krissel H; Schott A; Schadendorf D
    Melanoma Res; 2008 Aug; 18(4):274-8. PubMed ID: 18626312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.
    Hofmann MA; Kors C; Audring H; Walden P; Sterry W; Trefzer U
    J Immunother; 2008 Jun; 31(5):520-7. PubMed ID: 18463532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
    J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.
    Bajetta E; Del Vecchio M; Mortarini R; Nadeau R; Rakhit A; Rimassa L; Fowst C; Borri A; Anichini A; Parmiani G
    Clin Cancer Res; 1998 Jan; 4(1):75-85. PubMed ID: 9516955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
    Tarhini AA; Millward M; Mainwaring P; Kefford R; Logan T; Pavlick A; Kathman SJ; Laubscher KH; Dar MM; Kirkwood JM
    Cancer; 2009 Feb; 115(4):859-68. PubMed ID: 19140204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers.
    Geller MA; Cooley S; Argenta PA; Downs LS; Carson LF; Judson PL; Ghebre R; Weigel B; Panoskaltsis-Mortari A; Curtsinger J; Miller JS
    Cancer Immunol Immunother; 2010 Dec; 59(12):1877-1884. PubMed ID: 20820775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
    Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
    Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
    Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.